Email this article 
Hide
Show all
Editorial
Dolutegravir for second-line treatment: Programmatic implications of new evidence
Southern African Journal of HIV Medicine | Vol 23, No 1 | a1428 |
DOI: https://doi.org/10.4102/sajhivmed.v23i1.1428
| © 2022 Ying Zhao, Gary Maartens, Graeme Meintjes
| This work is licensed under CC Attribution 4.0
Submitted: 06 July 2022 | Published: 05 September 2022
Submitted: 06 July 2022 | Published: 05 September 2022
About the author(s)
Ying Zhao, Department of Medicine, Faculty of Health Science, University of Cape Town, Cape Town, South Africa; and, Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South AfricaGary Maartens, Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa; and, Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
Graeme Meintjes, Department of Medicine, Faculty of Health Science, University of Cape Town, Cape Town, South Africa; and, Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
Abstract
No abstract available.
Keywords
antiretroviral therapy; HIV; dolutegravir; second-line
Metrics
Total abstract views: 1895Total article views: 2658